Companies and Markets
Call us on +44 (0) 203 086 8600
Market Research A to Z | Company Profiles A to Z | RegisterRegister | Contact UsContact Us | Shopping Basket Shopping Basket
+44 (0) 203 086 8600 Call us on

HIV/AIDS therapeutics market led by Gilead as the greatest revenue shareholder

Industry Sector

Healthcare and Medical

Published

14 November 2012

Author

Matt Bodimeade

Type of News

Market

The HIV/AIDS therapeutics market has been forecast to increase at a compound annual growth rate (CAGR) of 7% over the next six years, increasing from a valuation of $13.5 billion in 2011, to hit a market value of $21.8 billion by 2018.

HIV endemic has had devastating economic, social, health and psychological impacts over the years affecting millions of households in a significant manner over the last decade. Despite the concrete efforts from authorities and various philanthropic institutions, the numbers are still on an upward trend with a total of 33.3 million HIV victims across the world recorded in 2009.

As a consequence of the on-going patent-cliff, the predicted growth rate is less than the market has experienced in previous years. Between 2004 and 2011, the market witnessed a more impressive CAGR of 12.5%, but due to the impending expiry of key medications, including Sustiva (efavirenz) and Reyataz (atazanavir) - both produced by Bristol-Myers Squibb - in 2014 and 2017 respectively, a more modest increase is predicted.

However, the HIV/AIDS therapeutics market is not without promise. The multi-class fixed dose combination tablet from Gilead Sciences, Atripla, saw global revenue increase from $2.9 billion in 2010 to $3.2 billion last year, while potential blockbuster Stribild was approved by the US Food and Drug Administration in August of this year and is expected to make a major impact.

Last year's sales figures show Gilead as being the greatest revenue shareholder of the world's top seven markets, with 36%. With less than half of that number, Bristol-Myers Squibb came second with 16%, while ViiV Healthcare completed the top three with a 13% segment.

For more information on the HIV/AIDS therapeutics market, see the latest research: HIV/AIDS Therapeutics Market

Follow us on Twitter @CandMResearch

Visitor Comments

All posts are pre-moderated and must obey the house rules.

Change Currency

GBP
USD

Change Currency

GBP
USD

Use our research skills: Get free support

Free Research Support: Let us do the work for you and find information from public and private sources of information. Contact us now and we can save you time and money.......Free Research Support

December Discounted Prices: Contact us to ask about our special discounts available in December

For the last month in 2014 we are offering discounted prices on a selection of new reports. Please contact us on 00 44 (0) 203 0868600 or via email (click here to email) to ask about prices and special discounts.

Available during December and the run-up to Christmas; Discounted prices on a selection of our reports.

Find all the research at the best prices. Great promotions being offered during December!

We are offering our clients substantial savings on the best research available during December. Please contact us either via emailor by calling our team to discuss your specific research needs on Tel: 00 44 (0) 203 0868600. We look forward to being able to find you the research you require at good prices.

Accessibility
Close

Contrast settings

Text size settings